A New Era: The Rise of Gene Therapy in NMIBC

EP: 1.Evolving Guidelines: Impact of Gene Therapy and BCG Failure Redefinitions on High-Risk NMIBC Patient Management

EP: 2.Applying Evidence Standards to Guide Gene Therapy Use in BCG-Unresponsive NMIBC

EP: 3.Impact of Real-World Treatment Experience on Gene Therapy Uptake in NMIBC

EP: 4.Navigating Challenges and Impact on Workflow with New NMIBC Therapies in Practice

EP: 5.Effective Strategies for Clinics Preparing to Implement Gene Therapy Into NMIBC Treatment Workflows

EP: 6.Reducing Clinical Resource Burden: Impact of Less Frequent NMIBC Therapy Administration

EP: 7.How Community-Based Gene Therapy Is Changing Treatment and Improving Quality of Life for Patients With BCG-Unresponsive NMIBC

EP: 8.Understanding NMIBC and Its Risk Factors

EP: 9.Navigating Treatment Burden in NMIBC

EP: 10.When BCG Falls Short: What’s Next for NMIBC Patients?

Now Viewing

EP: 11.A New Era: The Rise of Gene Therapy in NMIBC

Video content above is prompted by the following:

The introduction of gene therapy represents a paradigm shift in managing BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), offering urologists new tools with novel mechanisms of action. Nadofaragene firadenovec, the only FDA-approved gene-based therapy for this indication, utilizes a completely different approach to treating urothelial cell carcinoma. This adenoviral-based therapy maintains the familiar intravesical administration method that urologists are accustomed to, ensuring seamless integration into existing practice workflows.

A significant advantage of gene therapy lies in its dosing schedule, requiring only quarterly intravesical treatments compared with the weekly BCG schedule or frequent chemotherapy administrations. This reduced treatment frequency substantially decreases the burden on patients, particularly the older population most affected by NMIBC. Patients still require regular cystoscopic surveillance, but the fewer treatment visits offer considerable time savings and improved quality of life.

The broader implications of gene therapy extend beyond individual patient care to health care system efficiency. With an aging population and predicted urologist shortages, quarterly dosing helps alleviate physician time constraints and reduces nursing staff burden. Clinical trials and real-world evidence demonstrate promising response rates of 50% to 70% for gene-based therapy, combining excellent efficacy with reduced health care resource utilization. This efficiency allows urologists to allocate more time to other patients and disease types, addressing the growing demand for urological services across the health care system.